Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+15.95%
$11.25
100% positive prob.
5-Day Prediction
+21.02%
$11.74
100% positive prob.
20-Day Prediction
+14.41%
$11.10
95% positive prob.
SEC 8-K filings with transcript text
Feb 23, 2026 · 100% conf.
1D
+15.95%
$11.25
Act: +17.57%
5D
+21.02%
$11.74
Act: +7.34%
20D
+14.41%
$11.10
ibrx-20260223FALSE000132611000013261102026-02-232026-02-23
Washington, DC 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026
ImmunityBio, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3750743-1979754 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
3530 John Hopkins Court San Diego, California 92121 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (844) 696-5235
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per shareIBRXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐
Section 2 – Financial Information Item 2.02 Results of Operations and Financial Condition. On February 23, 2026, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the fourth quarter and year ended December 31, 2025, and its financial position as of December 31, 2025. The full text of the Company’s press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filings of the Company made under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Section 9 – Financial Statements and Exhibits. Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit Number Description of Exhibit
99.1**Press release dated February 23, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
** Furnished herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
Date: February 23, 2026 By:/s/ David C. Sachs David C. Sachs Chief Financial Officer
Jan 15, 2026 · 100% conf.
1D
+15.95%
$11.25
Act: +17.57%
5D
+21.02%
$11.74
Act: +7.34%
20D
+14.41%
$11.10
ibrx-20260115FALSE000132611000013261102026-01-152026-01-15
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2026
ImmunityBio, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3750743-1979754 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
3530 John Hopkins Court San Diego, California 92121 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (844) 696-5235
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per shareIBRXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 15, 2026, ImmunityBio, Inc. (the “Company”) issued a press release announcing certain preliminary, unaudited financial results for the fiscal quarter and full year ending December 31, 2025, along with additional Company updates. The results included in the press release reflect the Company’s preliminary estimates based solely upon information available to it as of the date of the press release, and the amounts reported are not a comprehensive statement of its operating results or financial position as of December 31, 2025. Any actual amounts that the Company reports in its Annual Report on Form 10-K for the year ended December 31, 2025 will be subject to its financial closing procedures and any final adjustments that may be made prior to the time its operating results and financial position for the fiscal quarter and year ended December 31, 2025 are finalized. As a result, these preliminary estimates may differ materially from the actual results that will be reflected in the Company’s consolidated financial statements for the fiscal year ended December 31, 2025 when they are completed and publicly disclosed in its Annual Report on Form 10-K. The full text of the Company’s press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filings of the Company made under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit NumberDescription of Exhibit
99.1**Press release dated January 15, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
** Furnished herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
Date: January 15, 2026 By:/s/ David C. Sachs David C. Sachs Chief Financial Officer
Nov 5, 2025
ibrx-20251104FALSE000132611000013261102025-11-042025-11-04
Washington, DC 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025
ImmunityBio, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3750743-1979754 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
3530 John Hopkins Court San Diego, California 92121 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (844) 696-5235
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per shareIBRXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐
Section 2 – Financial Information Item 2.02 Results of Operations and Financial Condition. On November 4, 2025, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the third quarter and nine months ended September 30, 2025, and its financial position as of September 30, 2025. The full text of the Company’s press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filings of the Company made under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Section 9 – Financial Statements and Exhibits. Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit Number Description of Exhibit
99.1**Press release dated November 4, 2025.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
** Furnished herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant
Date: November 4, 2025 By:/s/ David C. Sachs David C. Sachs Chief Financial Officer
This page provides ImmunityBio Inc. (IBRX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on IBRX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.